Moonwalk Biosciences

Private

#Cardiometabolic Diseases #Obesity #Epigenetics

Epigenetic medicines company developing precision epigenetics reprogramming for cardiometabolic diseases. Founded with $57M launch funding.

Company Info

Sector:Biologics

Headquarters:San Diego, California, USA

Founded:2021

Website:moonwalk.bio/

Upcoming Milestones & Key Dates

2027-H1

Regulatory

MWK-001 IND filing expected

2027-Q2

Clinical

First-in-human dosing expected

Clinical Development Pipeline

MWK-001

Target: Epigenetic reprogramming / RNAi

Obesity

Preclinical

Phase 1

Phase 2

Phase 3

Approved

MWK-002

Target: Epigenetic reprogramming

Cardiometabolic Disease

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Leadership Team

Alex Aravanis

CEO

Justin Valley

COO

Arash Jamshidi

President & CTO

Careers & Job Openings

See all open roles

Various

San Diego, CA

Apply Now →